

TRial of S^Tatin Therapy Effect on Androgen Status and Erectile function in Men

NCT07460960

Status	RECRUITING
Phase	Phase 2
Sponsor	Lomonosov Moscow State University Medical Research and Educational Center
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (5)

- male patients aged 40-65 years, sexually active
- high and very high risk of cardiovascular events (The Systematic Coronary Risk Evaluation 2 (SCORE2))
- absence of previous statin therapy for 3 months
- there are no known cardiovascular diseases requiring the appointment of statins in high doses from the start of treatment
- the invariance of concomitant therapy for 3 months, if the patient needs it.

Exclusion (12)

- known statin intolerance
 - known hypogonadism
 - persistent forms of atrial fibrillation
 - active malignant neoplasm requiring treatment at the time of screening
 - known chronic inflammatory diseases (rheumatoid arthritis, systemic connective tissue diseases, metabolically associated fatty liver disease, etc.)
- ... and 7 more (see full listing online)

Locations (1 total)

Lomonosov Moscow State University Medical Research and Educational Center Moscow, Moscow Region, Russia, 119620, Moscow, Russia